FDA lifts clinical hold on Avidity’s lead antibody conjugate therapy trial
The US Food and Drug Administration (FDA) has lifted the partial clinical hold on Avidity Biosciences’ investigational drug, delpacibart etedesiran…
News
Island Pharmaceuticals trials prevention and therapy benefit of dengue drug
NHS launches study of newborn blood test to detect 200 rare conditions
Immutep concludes participant enrolment in Phase II breast cancer trial
Palvella secures FDA grant for Phase III microcystic LMs treatment trial
Abivax enrols first participant in Phase IIb Crohn’s disease drug trial
Summit completes subject enrolment in Phase III NSCLC treatment trial
Processa Pharmaceuticals doses first subject in Phase II breast cancer trial
